Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Feb 2020 06:30 PM
RNS
Total Voting Rights
20 Feb 2020 07:00 AM
RNS
HEMO-CAR-T cells Effective Against AML in vivo
11 Feb 2020 07:00 AM
RNS
Approval and Issuance of U.S. Hu-PHEC Patent
31 Jan 2020 07:00 AM
RNS
Director/PDMR Shareholding
30 Jan 2020 02:05 PM
RNS
Placing and Subscription to raise £650,000
15 Jan 2020 12:30 PM
RNS
HEMO's CAR-T Cells Effective Against AML in vitro
18 Nov 2019 07:00 AM
RNS
Operational Update
12 Nov 2019 07:00 AM
RNS
Presentation at the Investival Showcase
06 Nov 2019 07:00 AM
RNS
Presentation at the NY Oncology Investor Conf.
23 Oct 2019 07:00 AM
RNS
Research Agreement with Global Pharma Company
21 Oct 2019 07:00 AM
RNS
Presentation at NY Stem Cell Foundation conference
30 Sep 2019 07:00 AM
RNS
Half-year Report
12 Sep 2019 07:00 AM
RNS
Hemogenyx scientific advisor receives Lasker Award
01 Aug 2019 07:00 AM
RNS
Total Voting Rights
12 Jul 2019 07:00 AM
RNS
CDX Patent Application
03 Jul 2019 07:00 AM
RNS
Director/PDMR Shareholding
28 Jun 2019 12:19 PM
RNS
Result of AGM
24 Jun 2019 07:00 AM
RNS
Development of ApbHC
12 Jun 2019 07:00 AM
RNS
CDX Effective as Conditioning Therapeutic in vivo
05 Jun 2019 08:15 AM
RNS
CDX Antibody is Effective against AML in vivo
30 May 2019 04:40 PM
RNS
Second Price Monitoring Extn
30 May 2019 04:35 PM
RNS
Price Monitoring Extension
30 May 2019 07:00 AM
RNS
CDX Antibody is Effective against ALL in vitro
28 May 2019 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
15 May 2019 07:00 AM
RNS
Variation of Terms of Warrant Instrument
01 May 2019 07:00 AM
RNS
Director/PDMR Shareholding
29 Apr 2019 03:10 PM
RNS
Final Results for the Year Ended 31 December 2018
30 Jan 2019 07:00 AM
RNS
Presentation at Cancer Immunotherapy Conference
07 Jan 2019 07:00 AM
RNS
Operations Update
20 Dec 2018 07:00 AM
RNS
Directorate Change
05 Nov 2018 07:00 AM
RNS
Directorate Change & Appointment
22 Oct 2018 07:00 AM
RNS
Orgenesis collaboration for Hu-PHEC development
19 Oct 2018 07:00 AM
RNS
Collaboration, License and Investment by Orgenesis
15 Oct 2018 07:00 AM
RNS
Collaboration with Johnson & Johnson Innovation
28 Sep 2018 09:30 AM
RNS
Half-year Report
28 Sep 2018 07:00 AM
RNS
Change of Adviser
03 Sep 2018 07:00 AM
RNS
Hemogenyx to present at Oxford conference
27 Jun 2018 11:39 AM
RNS
Result of AGM
08 Jun 2018 07:00 AM
RNS
Investor presentation
05 Jun 2018 06:05 PM
RNS
Posting of Annual Report & Notice of AGM
14 May 2018 07:00 AM
RNS
Development Agreement
08 May 2018 07:00 AM
RNS
Research Collaboration with Rockefeller University
30 Apr 2018 04:23 PM
RNS
Final Results
11 Apr 2018 05:15 PM
RNS
Director/PDMR Shareholding
03 Apr 2018 07:00 AM
RNS
Directorate Change
14 Mar 2018 11:05 AM
RNS
Second Price Monitoring Extn
14 Mar 2018 11:00 AM
RNS
Price Monitoring Extension
13 Mar 2018 07:00 AM
RNS
Collaboration with major US biotechnology company
06 Mar 2018 07:00 AM
RNS
Advisory Board Appointment
01 Mar 2018 07:00 AM
RNS
Align Research Initiation of Coverage

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100